South America Diabetes Care Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

South America Diabetes Care Devices Market Trends and Insights

Rising Diabetes Prevalence and Diagnosis Rates

The growing number of people living with diabetes provides the basic demand base for the South American diabetes care devices market. The adult diabetes population in South and Central America is projected to rise from 35.4 million in 2024 to 51.5 million by 2050, a 46% increase.^{[1]“IDF Diabetes Atlas, South and Central America Region,” IDF Atlas, diabetesatlas.org} Argentina recorded an age-standardized diabetes prevalence of 14% in 2024, followed by Chile at 12.2% and Brazil at 10.6%, supporting demand in markets with more developed private care channels. Gestational diabetes affected 12.5% of pregnancies in the region in 2024, or 967,000 live births, which creates a separate need for monitoring during pregnancy and can increase later awareness of diabetes care. As diagnosis programs reach more people, entry-level glucose meters, strips, lancets, and related support services become more relevant across the South American diabetes care devices market.

Growing Adoption of Continuous and Connected Monitoring

Continuous glucose monitoring is moving beyond specialist use in the leading countries of the South American diabetes care devices market. Abbott launched FreeStyle Libre 2 Plus in Brazil in June 2024 with automatic readings every minute, an 8.2% mean absolute relative difference, and 15-day sensor wear.^{[2]“Abbott Launches the FreeStyle Libre 2 Plus System in Brazil,” Abbott, bluestudio.estadao.com.br} A 2025 Brazilian study found that flash CGM users on a digital platform were younger than blood glucose meter users, with mean ages of 31.6 years and 36.2 years, respectively.^{[3]“Population Characteristics, Prescription Patterns and Glycemic Control of Users of Flash Glucose Monitoring Systems in Brazil, A Real-World Evidence Study,” Diabetology & Metabolic Syndrome, link.springer.com} The same study showed that use was concentrated in the higher-income Southeast, which reflects the continued importance of private affordability. Abbott and Medtronic formed a global alliance in August 2024 to link CGM and pump technologies, strengthening the role of interoperable systems in care pathways. These changes support recurring sensor demand and make switching between connected platforms less straightforward for patients and providers.

Expansion of Home-Based and Remote Diabetes Management

Home-based care is expanding the settings where the South American diabetes care devices market can serve people with diabetes. A 2024 Brazilian trial found that teleconsultation for Type 2 diabetes in the public health system achieved HbA1c reductions comparable with in-person care. This evidence supports the use of remote follow-up for patients who need regular monitoring but cannot easily attend specialist appointments. Argentina’s Jujuy province started a remote monitoring program for diabetes and renal disease in August 2024 using Bluetooth-connected devices and clinical supervision. Patients enrolled in remote programs need a steady supply of sensors, lancets, strips, or infusion sets, rather than a single device purchase. This makes recurring consumable demand an important feature of the South American diabetes care devices market as telehealth networks develop.

Public-Health Screening and Diabetes-Program Expansion

Public programs are expanding access to diabetes care products beyond commercially insured patients in the South American diabetes care devices market. Brazil’s Conitec recommended in November 2024 that rapid-acting and long-acting insulin analogs be extended to Type 2 patients in the Unified Health System, which can increase the use of insulin delivery products. In April 2025, Brazil’s Ministry of Health, Bio-Manguinhos, Biomm, and Gan&Lee formed a partnership for domestic insulin glargine production, supported by more than BRL 930 million (USD 179 million) in government investment. Public insulin access and clinical evidence for pediatric CGM use can both broaden demand for delivery and monitoring products.

High Out-of-Pocket Cost and Uneven Reimbursement

Affordability remains a primary constraint on advanced device adoption in the South American diabetes care devices market. Brazilian evidence showed that only 2.5% of flash CGM platform users were located in the lower-income North, while users were concentrated in the Southeast. Brazil’s public system covers glucose meters and strips, but most patient groups do not receive public reimbursement for CGM sensors. Imported premium systems are also exposed to currency depreciation, especially in Argentina, where exchange-rate changes can quickly reduce patient affordability. Reimbursement decisions and local purchasing capacity will determine how widely advanced monitoring can move beyond private-pay users.

Regulatory Fragmentation and Lengthy Device Registration

Regulatory requirements and uneven care infrastructure slow the broader development of the South American diabetes care devices market. ANVISA classifies most advanced CGM and pump systems as Class III or IV products under RDC 751/2022, requiring full marketing authorization and Good Manufacturing Practices certification. ANVISA’s 2024 update under IN 290 created an abbreviated review route for some Class III and IV products already authorized by Medical Device Single Audit Program member authorities. The ANVISA-ANMAT recognition arrangement simplified pathways for Class I and II products, but did not create the same simplification for most advanced CGM and pump systems. Outside major cities, limited specialist care, technical support, internet access, and device training also make sustained use more difficult. These limits affect the areas where the South American diabetes care devices market has the greatest need for lower-cost and easier-to-support solutions.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Device Type: Monitoring Devices Lead While CGM Changes the Mix

Monitoring devices held 61.24% of the South American diabetes care devices market share in 2025. Self-monitoring blood glucose systems, including meters, strips, and lancets, remain the standard approach within Brazil’s public procurement system and comparable public networks. Their scale comes from large tenders, familiar prescribing patterns, and the need for low-cost consumables. Continuous glucose monitoring is the fastest-growing device subcategory, with a forecasted CAGR of 6.23% through 2031. New sensor products have made CGM easier to use while retaining clinical accuracy. The South American diabetes care devices market size for monitoring, therefore, remains closely linked to basic products, even as sensor use expands in private care.

Management devices include insulin pumps, disposable pens, reusable pen cartridges, syringes, and jet injectors. Disposable pens and reusable cartridges account for most management-device volume because insulin delivery remains widely needed for insulin-treated patients. Novo Nordisk has manufacturing operations in Brazil that support insulin supply, while Sanofi and Eli Lilly maintain insulin delivery portfolios in the region. Pump adoption starts from a smaller base and is concentrated in specialist centers in São Paulo, Buenos Aires, and Santiago.

By Diabetes Type: Type 2 Volume Supports Wider Device Use

Type 2 diabetes accounted for 86.33% of demand in 2025 and is projected to grow at a 7.34% CAGR through 2031. This group shapes device volumes in the South American diabetes care devices industry because many patients use strips and meters, while some insulin-treated patients need delivery products. Brazil’s November 2024 recommendation to extend insulin analog coverage under SUS can move more Type 2 patients from oral therapy alone toward insulin delivery use. Screening and diagnosis can therefore increase demand for starter monitoring kits and ongoing supplies.

Type 1 diabetes represents a smaller share of patient volume but creates strong demand for CGM sensors, pumps, and closed-loop systems. Gestational diabetes and other conditions also require monitoring when more intensive glycemic control is needed. Gestational diabetes prevalence reached 12.5% in 2024, creating temporary but clinically important device demand during pregnancy.

By Distribution Channel: Hospital Pharmacies Lead While Online Pharmacies Expand

Hospital pharmacies held 43.45% of revenue in 2025, the largest distribution-channel position in the South American diabetes care devices market. Advanced devices are often dispensed through outpatient pharmacies linked to endocrinology centers and hospital formularies. Procurement committees can affect access for a large group of patients when they decide which products are included. Retail pharmacies serve substantial outpatient demand for meters, strips, lancets, and other recurring supplies. Hospital and retail presence remains important because many patients need professional guidance during initial device selection and use.

Online pharmacies are forecasted to grow at a 6.71% CAGR through 2031, making them the fastest-growing distribution channel. Growth is strongest in Brazil and Argentina, where smartphone access and digital prescriptions help patients obtain recurring supplies. Subscription bundles for strips and lancets can reduce the risk that patients delay refills between appointments. The online channel can support continuity of care, but its reach remains limited by connectivity, payment access, and delivery infrastructure in less urban areas.

By End-User: Hospitals and Clinics Lead, While Homecare Builds

Hospitals and clinics held 45.22% of end-user revenue in 2025. Specialist diabetes and endocrinology centers in São Paulo, Buenos Aires, Bogotá, and Santiago are key settings for the first use of CGM systems and pumps. These providers offer training that helps patients understand device use, alerts, and supply replacement. Many patients later buy consumables through retail or online pharmacies after the first hospital-based onboarding. This creates a handoff between institutional training and community distribution.

Homecare settings are projected to grow at a 5.91% CAGR through 2031. The South American diabetes care devices market benefits when remote programs move regular monitoring from facilities into patients’ homes. Argentina’s OSEP introduced a virtual patient-assistance initiative in November 2025 for 3,000 insulin-using patients using WhatsApp-based glycemic monitoring. Remote programs increase regular use of strips, sensors, lancets, and infusion sets while reducing some avoidable in-person visits. Their wider use depends on staffing, device support, connectivity, and public reimbursement.

Geography Analysis

Brazil held 46.37% of the South American diabetes care devices market share in 2025. The country has an estimated 20 million people with diabetes and a regulatory framework overseen by ANVISA. Central procurement through SUS supports substantial volumes of basic monitoring products. Private insurers support higher-cost CGM and pump use, especially in the Southeast. Brazil’s domestic insulin glargine initiative also targeted 20 million vials for SUS patients in 2025, which can support wider insulin treatment access. The country’s combination of scale, public procurement, private care, and local production makes it the main commercial base for the South American diabetes care devices market.

Argentina is the fastest-growing country, with a projected CAGR of 8.15% through 2031. Its diabetes prevalence was 14% in 2024, and specialist services are concentrated in Buenos Aires. Currency volatility continues to constrain the affordability of imported premium products. Chile and Colombia are the third and fourth-largest country markets, supported by concentrated urban medical services. Colombia has specialist concentration in major cities, but its separate device registration requirements add complexity for suppliers.

Peru, Bolivia, and the rest of South America have a less developed demand profile. Peru recorded a diabetes prevalence of 6.4% in 2024, while Bolivia recorded 3.4%, and Paraguay recorded 9.4%. These figures also reflect differences in diagnosis capacity and access to screening. The Inter-American Development Bank’s 2025 gSense grant supports digital diabetes management within Peru’s public primary-care network: lower incomes and limited specialist infrastructure favor affordable meters, strips, and lancets over premium CGM systems. Local distributor partnerships are important because they can reduce the difficulty of direct entry into the South American diabetes care devices market.